Agilon Health (AGL) Q3 2026 earnings review
Agilon raises its full-year outlook, but fourth-quarter math shows losses
Agilon Health, which partners with primary care doctors to manage senior healthcare budgets, beat its third-quarter profit plan and generated cash as medical claims stayed below estimates. Revenue rose 6% even with fewer patients on the platform, and chief executive Tim O’Rourke raised the full-year profit outlook for a third time this year. However, by our math the updated full-year plan still points to an operating loss of about $37 million in the fourth quarter.
| Revenue | $1,519M +6% from a year ago |
|---|---|
| Medical services expense ratio (MSER) | 88.5% 104.0% a year ago |
| Adjusted EBITDA (profit excluding one-offs) | $64M outlook: $(5)M to $5M |
| Full-year Adjusted EBITDA outlook | Raised $65M middle of the range: $150M |
⚖️ Verdict: 🟢 Bullish
The story got better because the profit recovery finally turned into cash, generating about $50 million of operating cash flow in the quarter by our math and lifting cash reserves to $312 million. Beating the prior plan's implied loss for the unconsolidated ACO partnerships also showed that the earlier outlook was cautious. One caution: higher doctor bonus accruals and stock compensation ate up over a third of the medical cost savings.
The question now is whether the implied fourth-quarter loss reflects another cautious forecast or a real jump in year-end medical costs entering 2027. If management is just holding back unconfirmed claims savings, fourth-quarter results will beat the plan again; if seasonal care and drug costs are rising, the company will enter 2027 losing money. Fourth-quarter medical cost ratios and the 2027 outlook will settle it.
🐂 Bull Case
Third Straight Outlook Raise on Lower Medical Costs
Agilon partners with primary care doctors to manage the total healthcare budget for senior patients. Chief executive Tim O’Rourke said third-quarter results "exceeded our expectations" as medical claims took a smaller share of revenue. The medical services expense ratio (MSER), the share of medical revenue spent on patient care, dropped 15.5 percentage points from a year ago to 88.5%.
- Third-quarter medical margin: $174.3 million by our math, against an outlook of $105–115 million
- Third-quarter Adjusted EBITDA (operating profit excluding one-offs): $63.7 million, against a break-even plan
- Full-year Adjusted EBITDA outlook: raised to $145–155 million from $75–95 million
- Unconsolidated ACO (Accountable Care Organization) Adjusted EBITDA outlook: raised to $40–45 million from $25–30 million
The company attributed the beat to "favorable claims development in the first half of 2026" and "higher-than-expected burden of illness performance", which are government payments for documenting how sick patients are. Because claims from earlier quarters keeps settling below initial estimates, management has now raised its full-year profit plan three times.
What to watch: the conference call breakdown of how much third-quarter profit came from prior-period claims versus third-quarter care. A smaller contribution from old claims would show that ongoing medical costs are genuinely cooling.
Operating Cash Turned Positive and Lifted Cash Reserves
For the first half of the year, Agilon's profit recovery sat in unpaid receivables while operations burned $33.6 million of cash. That pattern shifted in the third quarter. Nine-month operating cash flow reached positive $16.3 million, which means third-quarter operations generated $49.9 million of cash by our math.
After subtracting $3.3 million of third-quarter capital spending by our math, free cash flow was $46.6 million. Cash, restricted cash and marketable securities on the balance sheet rose by $54.5 million from June to $311.7 million, against $30.5 million of balance-sheet debt ($32 million in the release text). That gives the healthcare group breathing room above its $125 million year-end cash target.
What to watch: fourth-quarter operating cash flow and the timing of annual doctor bonus payouts. Accounts payable and accrued expenses rose by $198.5 million since December, and paying those bills will test how much cash stays on hand at year-end.
Higher Monthly Rates Drove Growth on Fewer Members
Agilon walked away from unprofitable insurance contracts at the start of 2026, so its average Medicare Advantage membership fell 4.3% from a year ago to 488,000. Even with fewer patients, total revenue grew 5.9% to $1.52 billion because the company charged higher monthly rates and recorded higher patient risk scores.
By our math, medical services revenue per average Medicare Advantage member rose 10.7% from a year ago to $1,037 a month. End-of-period Medicare Advantage membership also rose by 17,000 from June to 454,000, beating the 433,000–443,000 outlook. However, the full-year outlook of 445,000–450,000 ending members points to a drop of about 6,500 members in the fourth quarter by our math.
What to watch: the reconciliation between third-quarter average Medicare Advantage members of 488,000 and the updated full-year average outlook of 451,000–453,000. Management needs to explain why the third-quarter average jumped by 41,000 members while the ending count rose by 17,000.
🐻 Bear Case
The Raised Plan Still Points to a Fourth-Quarter Loss
O’Rourke said the quarter reflected "disciplined execution and operational progress" that positions the business for sustainable value. Yet the numbers inside the raised full-year outlook tell a more cautious story for the end of the year. Agilon has already earned $187.1 million of Adjusted EBITDA in the first nine months, which is $37.1 million above the middle of its new $145–155 million full-year target.
- Fourth-quarter Adjusted EBITDA implied by the full-year outlook: a loss of $32–42 million by our math
- Fourth-quarter MSER implied by the full-year outlook: about 97.0% by our math, up from 88.5% in the third quarter
- Fourth-quarter revenue implied by the full-year outlook: $1.45 billion by our math, down 7.9% from a year ago
A planned fourth-quarter loss of roughly $37 million is nearly identical to the second-half loss the prior outlook implied three months ago. Either management is setting another low bar by assuming no more favorable claims updates, or seasonal medical costs will erase the third quarter's margin gains entering 2027.
What to watch: fourth-quarter MSER when full-year results arrive. A ratio near 97% would mean the company enters 2027 losing money on operations, whereas a result near 90% would show that management padded the fourth-quarter outlook.
Doctor Bonuses and Overhead Ate Into the Margin Recovery
When medical claims fall below budget, Agilon shares the savings with its partner physicians and pays higher performance bonuses to employees. Those two expense lines absorbed over a third of the improvement in direct medical costs during the third quarter.
Other medical expenses, which represent surplus-sharing payments to partner doctors and care management costs, rose from $13.5 million a year ago to $78.0 million. By our math, that line climbed 4.2 percentage points of revenue to 5.1%. General and administrative expenses (corporate overhead and platform support) also rose 19.5% to $67.1 million, or 0.5 percentage points of revenue, as stock-based compensation jumped from $7.5 million to $18.9 million.
What to watch: platform support costs in the fourth quarter. Platform support rose 14.8% from a year ago to $44.4 million this quarter despite past cost-cutting programmes, and another increase would show that fixed overhead is still rising.
Risks this quarter didn't answer
Several standing risks from prior quarters depend on conference call commentary or quarterly filing footnotes that are not in the earnings release.
- 2027 contract renewals and risk scores: management previously warned that 2027 risk-score gains will step down and that half of payer contracts were open; the fourth-quarter call will show where 2027 pricing landed.
- Claims reserve breakdown: the release states that MSER benefited from first-half claims development and patient risk scores, but only the quarterly filing will show the exact dollar split.
- Clinical pathway and data pipeline metrics: the release gives no update on the rollout of dementia and lung pathways or the percentage of members covered by the data pipeline.
- Payer concentration and legal disputes: updates on the two insurers that made up 45% of revenue and the pending shareholder lawsuits await the quarterly Form 10-Q filing.
👓 Other Themes
Management Replaced Dollar Medical Margin With an Expense Ratio
Agilon changed its headline profitability measure this quarter. In both the summary table and the full-year outlook, the company replaced dollar medical margin with the medical services expense ratio (MSER), which divides direct patient care costs by medical services revenue. Both figures come from the same two income statement lines, so investors can still compute third-quarter medical margin at $174.3 million by our math.
💲 Other KPIs
Receivables — money owed by insurers for patient care and risk-score adjustments — fell 4.0% from $1,059.8 million in June, after climbing for two straight quarters. Compared with a year ago, receivables are up 7.4% against 5.9% revenue growth. Starting to collect those balances helped turn operating cash flow positive this quarter.
Partnered ACO entities, which Agilon does not consolidate on its income statement, generated $429.1 million of medical revenue. That is down 6.4% from a year ago by our math, but up 13.1% from $379.3 million in the second quarter. Their MSER was 91.4%, and they contributed $11 million to Agilon's Adjusted EBITDA.
Weighted average diluted shares rose 6.7% from a year ago by our math, and increased by 475,000 shares from the second quarter. Basic shares barely moved at 16.79 million, up 1.3% from a year ago. The diluted count rose because profitable quarters require the US company to include employee stock options and awards in the per-share calculation.
🔮 Guidance
Raised. The middle of the full-year range moved up $62.5 million to $5,880 million, which leaves full-year revenue down 0.9% from 2025 by our math. That implies fourth-quarter revenue of $1,445 million by our math, down 7.9% from a year ago. It is the third raise this year, and each step has been smaller: +$247.5M, +$75.0M, +$62.5M.
Raised (improved). Management lowered its full-year medical cost ratio outlook by 1.25 percentage points at the middle of the range to 90.4%. Because MSER ran at 88.3% across the first nine months, the full-year plan implies a fourth-quarter ratio of about 97.0% by our math, the highest cost ratio of the year.
Raised. The middle of the range rose by $65 million to $150 million, including $40–45 million from unconsolidated ACO entities (up from $25–30 million). Because nine-month Adjusted EBITDA is already $187.1 million, the outlook leaves a fourth-quarter loss of $37.1 million at the middle of the range by our math. It is the third raise this year: +$25M, +$60M, +$65M.
Raised. The middle of the range moved up by 7,500 members to 447,500, which is down 12.4% from the end of 2025 by our math. Because third-quarter membership reached 454,000, the updated outlook implies a drop of 4,000 to 9,000 members during the fourth quarter.
Raised. Management lifted the full-year average by 11,500 members at the middle of the range to 452,000, down 11.4% from 2025 by our math. The third-quarter average of 488,000 ran well above the new full-year range.
Raised. The middle of the range increased by 7,500 beneficiaries to 110,000 after holding unchanged for three quarters. Against 112,000 beneficiaries at the end of September, the plan points to flat to slightly lower membership in the fourth quarter.
Raised. Total platform membership rose by 15,000 at the middle of the range to 557,500, reflecting the identical 7,500-member increases in both Medicare Advantage and ACO beneficiaries. By our math, that implies a fourth-quarter decline of 4,000 to 13,000 total members from September's 566,000.
Unchanged. Management kept the full-year budget for entering new markets at $15 million for a fourth straight quarter. Because nine-month spending totaled $8.3 million ($6.4 million in overhead and $1.9 million in other medical costs), the plan leaves $6.7 million of spending for the fourth quarter by our math, up from $2.4 million in the third quarter.
❓ Key Questions
How much of Q3 profit came from earlier quarters?
The release says third-quarter medical costs benefited from favorable claims development from the first half of 2026 and higher risk-score performance. Investors need the exact dollar amounts to see what the third quarter earned on its own.
Why does the raised outlook still imply a Q4 loss?
Nine-month Adjusted EBITDA of $187.1 million sits $37.1 million above the middle of the new full-year range. Management did not provide a fourth-quarter outlook table, leaving open what drives the implied fourth-quarter MSER to 97%.
Why did Q3 average MA members jump to 488,000?
End-of-period Medicare Advantage members rose from 437,000 in June to 454,000 in September, yet the third-quarter average was 488,000 and the full-year average outlook is only 451,000–453,000. Did a retroactive contract adjustment inflate the third-quarter average?
Where did 2027 payer contract renewals land?
Management previously said about half of its insurance contracts were up for renewal for 2027, with negotiations hitting full stride in the third quarter. The release gives no update on 2027 pricing or expected membership.